Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

Investegate announcements from Junshi Biosciences, Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

Related Keywords

Guangzhou ,Guangdong ,China ,Tongji ,Sichuan ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Peking ,Canada ,Jiaotong ,Guizhou ,Chicago ,Illinois ,San Francisco ,California ,Chinese ,American ,Russellj Schilder ,Junshi Bioscience ,Jie Wang ,Jianjun Zou ,Xinan Sheng ,Jun Ma ,Jun Zhu ,Yiran Huang ,Junshi Biosciences ,Zhi Li ,Jun Guo ,American Society Of Clinical Oncology ,Shanghai Jiaotong University School Of Medicine ,Pr Team ,Institute Of Microbiology The Chinese Academy ,Harbin Institute Of Hematology Oncology ,Global Research ,Ir Team ,University Cancer Hospital Institute ,Tongji University ,Thomas Jefferson University ,National Reimbursement Drug List ,National Cancer Center ,National Medical Products Administration ,Chinese Academy Of Medical Sciences ,Shanghai Junshi Biosciences Co Ltd ,Junshi Biosciences Highlights Pipeline Advances ,Immuno Oncology Through Nearly ,Clinical Oncology ,Annual Meeting ,Development President ,Professor Jun Zhu ,Peking University Cancer Hospital ,Harbin Institute ,Professor Russell ,Professor Jun Guo ,Professor Yiran Huang ,Ren Ji Hospital ,Shanghai Jiaotong University School ,Professor Ye Guo ,Shanghai East Hospital ,Progression Free Survival ,Interim Overall Survival ,Biomarker Analyses ,Professor Jie Wang ,Chinese Academy ,Medical Sciences ,New Drug Application ,Southeast Asia ,Breakthrough Therapy ,Biologics License Application ,Fast Track ,Orphan Drug Designation ,Emergency Use Authorizations ,Investegate Announcements ,Investegate Company Announcements ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,